|
| Q-5. |
What is the rationale for the demerger of the R&D company? |
|
|
The R&D company will have projects in the areas of new molecule and novel drug delivery systems, projects that will earn intellectual property and revenues from international markets. The rationale for the demerger is to allow the right focus and resource commitment for long term projects that have a different timeframe to completion. |
|
|
| Q-6. |
What are the current projects in NCE and NDDS research? |
|
|
The details of the current projects will be shared a month prior to the listing of the new company. The NDDS projects are on four platforms- CR/SR, DPI, biodegradable membranes and targeted drug delivery. The NCE projects follow a therapeutic analogue based approach in areas of known biology. |
|
|
| Q-7. |
How many factories are USFDA approved? How many factories are in the US? |
|
|
Two API manufacturing factories in India, in Panoli and Ahmednagar, hold USFDA approval. Three dosage form plants in the US- Detroit (Caraco), and plants at Bryan, Ohio and at Cranbury hold or will be shortly submitted for USFDA approval. One dosage form plant in India, in Halol, holds USFDA approval, for tablets, injectables and nasal sprays. |
|
|
| Q-8. |
How many people work at Sun Pharma? How many people are in marketing? How many people are in research? |
|
|
Across the group, including subsidiaries, over 5,000 people work at Sun Pharma. About 2,500 people work in marketing and sales in India, and 260 in international markets (other than the US). About 500 scientist work in research. |
|
|
|
|
|
News Articles
Contact Us
